Company Encyclopedia
View More
name
Somnomed Limited
SOM.AU
News
View More

Somnomed Limited Announces Director’s Increased Stake

Somnomed Limited announced that director Michael Gordon has acquired 200,000 additional options, increasing his total to 885,000 options. This change, approved at the company's Annual General Meeting, aims to align the director's interests with the company's growth objectives. The latest analyst rating for Somnomed Limited (AU:SOM) is a Hold with a A$1.00 price target. Somnomed Limited specializes in oral appliance therapy products for sleep-related disorders.

Tip Ranks·
Tip Ranks·

Somnomed Limited Issues New Equity Securities

Somnomed Limited has announced the issuance of unquoted equity securities, specifically options with varying expiration dates and exercise prices. This move is expected to impact the company's financial strategy by potentially increasing its capital base and providing incentives for stakeholders. The most recent analyst rating on Somnomed Limited stock is a Hold with a A$1.00 price target.

Tip Ranks·
Tip Ranks·

SomnoMed Boosts Managed Care Infrastructure with Major Investment

SomnoMed Limited has announced a major investment in its managed care infrastructure in the U.S. to enhance support for health plans, provider networks, and care programs. This expansion includes centralized billing, provider credentialing, and streamlined administration. Jennifer Larsen has been promoted to Strategic Account Manager to support this growth. The information was originally published by SomnoMed Limited via Business Wire.

Reuters·
Reuters·

Canaccord Genuity Keeps Their Buy Rating on Somnomed Limited (SOMNF)

In addition to Canaccord Genuity, Somnomed Limited also received a Buy from Wilsons’s Shane Storey in a report issued on September 24. However, on October 2, TR | OpenAI – 4o reiterated a Hold rating on Somnomed Limited (Other OTC: SOMNF).

Tip Ranks·
Tip Ranks·
© 2025 Longbridge｜Disclaimer